Related Experiment Videos
Intravenous gamma-globulin treatment in Kawasaki disease
1Department of Pediatrics, Nihon University, School of Medicine, Tokyo, Japan.
Insights
Gamma globulin effectively reduces coronary artery abnormalities in Kawasaki disease, with higher doses and intact forms showing greater efficacy. This study established guidelines for gamma globulin use in affected children.
Area of Science:
- Pediatrics
- Immunology
- Cardiology
Background:
- Kawasaki disease is a leading cause of acquired heart disease in children.
- Coronary artery abnormalities are a significant complication of Kawasaki disease.
- Gamma globulin is a standard treatment, but optimal dosing and type require further study.
Purpose of the Study:
- To evaluate the effectiveness of different doses and types of gamma globulin in Kawasaki disease.
- To establish clear indications for gamma globulin treatment based on patient criteria.
- To assess the impact of gamma globulin on preventing coronary artery abnormalities.
Main Methods:
- A multicenter randomized controlled study was conducted.
- Patients received varying doses and types of gamma globulin (intact vs. pepsin-treated).
- Criteria for gamma globulin indication included WBC, platelet count, CRP, Hct, albumin, age, and sex.
Main Results:
- Gamma globulin significantly lowered the incidence of coronary artery abnormalities.
- Treatment effectiveness was dose-dependent.
- Intact gamma globulin was more effective than pepsin-treated gamma globulin.
- In children not receiving gamma globulin, coronary artery dilatations were observed.
Conclusions:
- Gamma globulin is effective in preventing coronary artery abnormalities in Kawasaki disease.
- Dose and type of gamma globulin influence treatment outcomes.
- Established guidelines appear satisfactory for determining gamma globulin indications.
Abstract:
A multicenter randomized controlled study was carried out to assess the effectiveness of different, doses and kinds of gamma-globulin in Kawasaki disease. Gamma globulin lowered the incidence of coronary artery abnormalities. The effect of gamma-globulin was dose dependent. The intact type was more effective than the pepsin treated type. To establish the indications for gamma-globulin, a study was made of patients who received neither gamma-globulin nor indomethacin and who, within nine days of onset of illness, satisfied at least four of the following criteria: (1) WBC: more than 12,000/mm; (2) platelet count: less than 35 X 10(4)/mm; (3) CRP: more than 3+; (4) Hct: less than 35%; (5) albumin: less than 3.5 g/dl (6) age: 12 months or less; (7) male sex. This prospective study is continuing. Of 143 children, 73.4% received gamma-globulin, and only two demonstrated small dilatations of the coronary arteries in children who did not receive gamma-globulin. These guidelines seem satisfactory to establish the indications for gamma-globulin in Kawasaki disease.